A Method of Remyelinating Congenitally Dysmyelinated Forebrains

Brief Description

A method of remyelinating axons using oligodendrocyte progenitor cells.

 

Problem Solved by this Technology

A broad range of diseases -- from the inherited leukodystrophies to 25 vascular leukoencephalopathies to multiple sclerosis -- result from myelin injury or loss. In the pediatric leukodystrophies, in particular, compact myelin either fails to develop properly, or is injured in the setting of toxic storage abnormalities. Recent studies have focused on the use of transplanted oligodendrocytes or their progenitors for the treatment of these congenital myelin diseases.

 

Applications

This technology involves a method of remyelinating axons in conditions mediated by a loss of myelin or a loss of oligodendrocytes by treating the axons with oligodendrocyte progenitor cells. An in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types is also involved, resulting in the availability of the stem cells for therapy.

 

URV Reference Number: 6-2135

Patent Information:
Title Country Patent No. Issued Date
Myelination of Congenitally Dysmyelinated Forebrains Using Oligodendyocyte Progenitor Cells United States 8,206,699 6/26/2012
Category(s):
Therapeutic
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Steven Goldman
Martha Windrem
Neeta Roy
Keywords:
Neurological
Stem Cell
Stem Cell Technology